Impact of EDUcation Strategy on Patients With COLorectal CANCER or Advanced Adenoma in the Detection of Colorectal Cancer of Their First-degree Relatives

NCT ID: NCT03084133

Last Updated: 2019-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-10

Study Completion Date

2019-01-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The relative risk of colorectal cancer (CRC) is increased in first-degree relatives of patients with CRC or advanced adenoma. In the high-risk CCR population defined by a family history at the first stage of CRC or advanced adenoma before age 60, total colonoscopy is the recommended screening test. In France, the rate of screening colonoscopy in this population at high risk of CRC is insufficient, which limits the effectiveness of this targeted screening.

The main reason for this low participation rate is that most patients undergoing RCC or advanced adenoma are unaware of the family implications of their diagnosis and therefore reluctant to disseminate this information to their patients Related matters. The need for a better perception of the personal risk of CRC in first-degree relatives of patients with CRC or advanced adenoma, with the expected coronary adherence to increasing screening, requires a good understanding of risk through Clear, adapted and comprehensible information that can be relayed personally by the case-index.

The objective of this project is to develop a personalized prevention and screening program for the JRC in order to meet the needs of the relatives of the sick. The means of intervention that will be implemented respond to the need to better take into account the level of CRC risk in a family-based CRC screening and prevention approach adapted to a high-risk CRC group characterized by Family history at the first stage of CRC or advanced adenoma and, consequently, to improve the information of the subjects concerned by screening and prevention of CRC.

The aim of the case-index education is to induce its intervention with its relatives to promote CCR screening. The use of the index case, as a means of providing information to relatives, implies an educational and psychological approach, based on evidence, but adapted and personalized.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The relative risk of colorectal cancer (CRC) is increased in first-degree relatives of patients with CRC or advanced adenoma. In the high-risk CCR population defined by a family history at the first stage of CRC or advanced adenoma before age 60, total colonoscopy is the recommended screening test. In France, the rate of screening colonoscopy in this population at high risk of CRC is insufficient, which limits the effectiveness of this targeted screening.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Colorectal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

"Intervention group" means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.

"Control group": provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the case-index according to its usual practice and adapted to the level of understanding of Case-index.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Therapeutic Education Strategy

Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.

Intervention 'Therapeutic Education Strategy'

Group Type EXPERIMENTAL

Therapeutic Education Strategy

Intervention Type BEHAVIORAL

In the experimental arm of the study ("intervention group"), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the "intention" of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a "competence" approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002).

Control group

Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Therapeutic Education Strategy

In the experimental arm of the study ("intervention group"), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the "intention" of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a "competence" approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002).

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Index case:

* Patients with colorectal adenocarcinoma or advanced adenoma diagnosed (definition of advanced adenoma (Winawer, 2006): adenoma of diameter ≥ 10 mm and / or severe dysplasia and / or with a villous contingent).
* Patients with at least one relative of the first degree belonging to the target population of the screening strategy evaluated (between 40 and 75 years of age and less than 10 years of age of the case-index) and residing in France.
* Affiliation of the patient to a social security scheme (including CMU).
* Understanding of the French language.

Related:

* They correspond to the target population at high risk of colorectal cancer targeted by this program of promotion of colonoscopy screening:
* Subjects related to 1st degree to the index case and in contact with it.
* Age between 40 and 75 years of age or less than 10 years of age of the index case.
* Resides in France

Exclusion Criteria

Index case :

* Chronic inflammatory bowel disease.
* Genetic predisposition syndrome identified with colorectal cancer (Lynch syndrome, familial polyposis linked to the APC and MYH genes).
* Patient's knowledge of a first-degree relative with colorectal adenocarcinoma or advanced adenoma.
* Isolated patient of his / her first-degree relatives and not wishing to re-establish contact with them.
* Advanced colorectal cancer with a life expectancy \<6 months and / or a WHO ≥ 2 general condition.
* Transmission of information to the family already carried out.

Related :

\- Not applicable
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role collaborator

Nantes University Hospital

OTHER

Sponsor Role collaborator

Centre Hospitalier de Dreux

OTHER

Sponsor Role collaborator

Hospital BLOIS

UNKNOWN

Sponsor Role collaborator

Hospital LOCHES

UNKNOWN

Sponsor Role collaborator

Poitiers University Hospital

OTHER

Sponsor Role collaborator

UNIVERSITY HOSPITAL, ORLEANS

UNKNOWN

Sponsor Role collaborator

Clinic LE MANS

UNKNOWN

Sponsor Role collaborator

University Hospital, Tours

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

CAROLI BOSC Françis- Xavier, Pr

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Angers

MATYSIAK-BUDNIK Tamara, Pr

Role: PRINCIPAL_INVESTIGATOR

Nantes University Hospital

LANDAU Alain, Dr

Role: PRINCIPAL_INVESTIGATOR

CHG DREUX

GARGOT Denis, Dr

Role: PRINCIPAL_INVESTIGATOR

CHG BLOIS

BARBIEUX Jean- Pierre, Dr

Role: PRINCIPAL_INVESTIGATOR

CHG LOCHES

TOUGERON David, Pr

Role: PRINCIPAL_INVESTIGATOR

CHU Poitiers

LEGOUX Jean- Louis, Dr

Role: PRINCIPAL_INVESTIGATOR

CHR ORLEANS

BOURGEOIS Hugues, Dr

Role: PRINCIPAL_INVESTIGATOR

Clinic Victor Hugo LE MANS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service d'Hépatogastro-entérologie CHU ANGERS

Angers, , France

Site Status

Service d'Hépatogastro-entérologie CHG BLOIS

Blois, , France

Site Status

Service d'Hépatogastro-entérologie CHG de DREUX

Dreux, , France

Site Status

Service de Médecine CHG de Loches

Loches, , France

Site Status

Service d'Hépatogastro-entérologie CHU de NANTES

Nantes, , France

Site Status

Service d'Hépatogastro-entérologie CHR d'Orléans

Orléans, , France

Site Status

Service d'Hépatogastro-entérologie CHU POITIERS

Poitiers, , France

Site Status

Service d'Hépatogastro-entérologie CHRU de TOURS

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-A01514-45

Identifier Type: OTHER

Identifier Source: secondary_id

INCA14-TL/EDUCANCOLAGE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.